A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome-Reference-Cited by-同舟云学术

A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome

Published:2019-03 Issue:3 Volume:111 Page:571-578.e1
ISSN:0015-0282
Container-title:Fertility and Sterility
language:en
Short-container-title:Fertility and Sterility

Author:

Mejia Rachel B.,Summers Karen M.,Kresowik Jessica D.,Van Voorhis Bradley J.

Funder

University of Iowa

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference13 articles.

1. Polycystic ovary syndrome;Norman;Lancet,2007

2. Sonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth;Gonen;Hum Reprod,1990

3. Cervical mucus score and in vitro sperm mucus interaction in spontaneous and clomiphene citrate cycles;Randall;Fertil Steril,1991

4. Aromatase inhibitors in ovarian stimulation;Casper;The J Steroid Biochem Mol Biol,2007

5. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome;Legro;N Engl J Med,2014

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Letrozole and Crocin Combination on Sperm Motility and Biochemical Markers in Azoospermia: Insights from Gene Expression Analysis;2024-09-10

2. Impact of Letrozole on Mature Follicle Rate in Treatment of Subfertility Due to Polycystic Ovarian Syndrome;Pakistan Journal of Health Sciences;2024-08-31

3. Bilateral tubal ectopic pregnancy following induction ovulation can be missed in emergent ultrasonography: Case report;International Journal of Surgery Case Reports;2024-08

4. A EFICÁCIA DOS TRATAMENTOS FARMACOLÓGICOS PARA INFERTILIDADE NA MULHER COM SÍNDROME DOS OVÁRIOS POLICÍSTICOS: UMA REVISÃO SISTEMÁTICA;Revista Contemporânea;2024-06-27

5. Safety assessment of clomiphene: a real-world pharmacovigilance analysis from the Food and Drug Administration adverse event reporting system;Expert Opinion on Drug Safety;2024-05-23